Transmissible spongiform encephalopathies (TSEs) or prion diseases are characterized by the accumulation in affected tissues of the abnormal prion protein PrP. We previously demonstrated PrP in the blood of macaques experimentally infected with variant Creutzfeldt-Jakob disease (vCJD), a human TSE, months to years prior to clinical onset. That work supported the prospect of using PrP as a blood biomarker to detect vCJD and possibly other human TSEs before the onset of overt illness. However, our results also raised questions about the origin of PrP detected in blood early after inoculation and the effects of dose and route on the timing of the appearance of PrP. To investigate these questions, we inoculated vCJD-susceptible transgenic mice and non-infectable prion protein-knockout mice under inoculation conditions resembling those used in macaques, with additional controls. We assayed PrP in mouse blood using the protein misfolding cyclic amplification (PMCA) method. PrP from the inoculum cleared from the blood of all mice before 2 months post-inoculation (mpi). Mouse PrP generated de novo appeared in blood after 2 mpi. These results were consistent regardless of dose or inoculation route. We also demonstrated that a commercial ELISA-like PrP test detected and quantified PMCA products and provided a useful alternative to Western blots.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384726 | PMC |
http://dx.doi.org/10.3390/v15071466 | DOI Listing |
Arch Phys Med Rehabil
January 2025
Department of Physical Medicine and Rehabilitation, School of Medicine, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey.
Objectives: To evaluate the combined effect of two different regenerative therapies, extracorporeal shock wave therapy (ESWT) and platelet-rich plasma (PRP), along with therapeutic exercise, in patients with lateral epicondylitis (LE).
Design: Prospective, Randomized, Sham-Controlled Trial.
Settings: Outpatient clinic.
Maturitas
January 2025
Faculty of Medicine, Geneva University, 1205 Geneva, Switzerland; Department of Pediatrics, Gynecology and Obstetrics, Division of Gynecology, Urogynecology Unit, Geneva University Hospitals, Geneva, Switzerland. Electronic address:
Objective: Many postmenopausal women suffering from vulvovaginal atrophy are looking for non-hormonal treatments. Platelet-rich plasma (PRP) therapy has emerged as a novel and promising approach for gynecological applications. PRP is an autologous blood product rich in growth factors used to stimulate tissue regeneration.
View Article and Find Full Text PDFPLoS Pathog
January 2025
Center for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
Prion diseases, particularly sporadic cases, pose a challenge due to their complex nature and heterogeneity. The underlying mechanism of the spontaneous conversion from PrPC to PrPSc, the hallmark of prion diseases, remains elusive. To shed light on this process and the involvement of cofactors, we have developed an in vitro system that faithfully mimics spontaneous prion misfolding using minimal components.
View Article and Find Full Text PDFPharmacol Res Perspect
February 2025
Medication Safety (Formulary) Clinical Excellence Commission, Sydney, New South Wales, Australia.
New onset insomnia is often experienced by patients during hospitalization due to environmental disruptions, pain and increased patient care activities. Patient distress arising from poor sleep quality and quantity often results in the prescribing of hypnotics. Melatonin use in hospital settings is common and is increasingly used for off label indications including primary insomnia in those aged < 55 years, prevention of delirium and to facilitate benzodiazepine discontinuation.
View Article and Find Full Text PDFJ Cosmet Dermatol
January 2025
Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Background: There is no definitive solution for the treatment of striae distensae (SD), and effectiveness of each treatment method remains controversial. We aimed to investigate and compare the efficacy of the combination of Erbium YAG (Er:YAG) laser and stromal vascular fraction (SVF), the combination of Er:YAG laser and platelet-rich plasma (PRP) and Er:YAG laser plus saline in the treatment of SD.
Materials And Methods: In 12 participating patients with at least three lesions (36 lesions in total), each lesion was treated with an Er:YAG laser.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!